• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » 2015 Lasker Award winners announced

2015 Lasker Award winners announced

September 8, 2015
CenterWatch Staff

The Albert and Mary Lasker Foundation has given the 2015 Lasker Awards to James Allison, Evelyn Witkin, Stephen Elledge and the organization Medecins Sans Frontieres, or Doctors Without Borders.

Allison won the Lasker-DeBakey Clinical Medical Research Award for his discoveries regarding checkpoint inhibition and his role in developing Yervoy (ipilimumab from Bristol-Myers Squibb), the first FDA-approved checkpoint inhibitor and, at the time of its approval in 2011, the first drug that enabled long-term survival of some metastatic melanoma patients.

For now, such long-term survival is the fate of a lucky few. About 22 percent of patients treated with Yervoy live for more than a year. But that percentage translates into thousands of patients, and the search for combination treatment that will raise that survival rate is both an active area of research and one where the optimism is palpable.

Elledge and Witkin received the Albert Lasker Basic Medical Research Award for “discoveries concerning the DNA-damage response—a fundamental mechanism that protects the genomes of all living organisms.” Witkin studied the DNA damage response in bacteria, while Elledge uncovered its molecular mechanisms in more complex organisms.

The DNA damage response—the means by which cells protect themselves from the constant stream of injuries that their genetic material is subject to—is as basic a biological mechanism as they come. But understanding it also has had medical payoffs. BRCA-mutated cells are exquisitely sensitive to inhibition of the DNA damage repair enzyme poly (ADP-ribose) polymerase, or PARP. Lynparza (olaparib from AstraZeneca) is a PARP inhibitor that is approved for the treatment of BRCA-mutated ovarian cancers, and other PARP inhibitors are in clinical trials.

Allison, 67, is a professor of immunology, chairman of the immunology department and executive director of the immunotherapy platform at the University of Texas MD Anderson Cancer Center. Elledge, 59, is a professor of genetics and medicine at Harvard Medical School and the Brigham and Women’s Hospital. Witkin, 94, is a bacterial geneticist and professor emerita at the Waksman Institute of Microbiology at Rutgers University.

Medecins Sans Frontieres was given the Lasker-Bloomberg Public Service Award for “bold leadership” in fighting the Ebola epidemic in West Africa, “and for sustained and effective front-line responses to health emergencies,” the Lasker Foundation said in a prepared statement.

Each award includes a $250,000 prize and will be presented in Manhattan, N.Y., on Sept. 18. Many Lasker recipients have gone on to receive Nobel Prizes, including 44 in the last three decades, according to the foundation.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing